retatrutide phase 3 triumph for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the registrational clinical trials - Giblin - 2026 - Diabetes, Obesity and Metabolism TRIUMPH-4: Retatrutide Beat Every Prediction

"As a convenient, once-daily oral pill that delivers meaningful weight loss, this is obesity care designed for the real world." How do GLP-1 drugs work

Is Hers safe, and what monitoring is provided

The study showed a 13% reduction in major adverse cardiovascular events (MACE), a composite endpoint for cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients treated with liraglutide compared with placebo at a mean follow-up of 3.8 years (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.780.97) and a significant reduction in cardiovascular death (HR 0.78, 95% CI 0.660.93)

All current use is strictly research-use-only